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peutic intervention and trial monitoring and outcome evaluation. Complicating
this situation is inconsistencies in CFS case definition. The main objective is to
provide a critical review of the similarities and differences between the varying
approaches to CFS case definition. The conflicts and controversies that have
emerged as a result of the differing definitional criterion for CFS are highlighted
and the potential impact on future research is identified. A critical review of the
most frequently used case definitions in CFS was conducted. There are currently
five case definitions of CFS; however, the most prominent is the 1994 Centre for
Disease Control and PreventionCaseDefinitions. However, prima face comparative
advantages of this definition are elusive and indeed, it has been widely criticized
for its lack of specificity. Counterintuitively, there is little compelling evidence to
support the efficacy of any of the case definitions have produced evidence to dem-
onstrate their accuracy or precision at defining cases of CFS. A summary descrip-
tion of the symptom profile for each of the case definitions is provided. The incon-
sistencies that have emerged in CFS research as a consequence of differing
approaches to case definition are contrasted and discussed. Clinical and research
implications are highlighted.
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IQWIG AND HIQA, WHAT ARE THEY GOOD FOR? THE EVOLUTION OF THE HTA
AGENCY: TIME FROM CREATION TO FIRST ASSESSMENT AND IMPACTFUL
APPRAISAL
Green MJ
HERON Evidence Development LLC, Somerville, NJ, USA
OBJECTIVES: To evaluate the time spent from the creation or charter of an HTA
agency to endpoints indicating their effectiveness, such as publication of assess-
ments and evidence of the incorporation of assessment into meaningful appraisal
influencing patient access to health technologies. METHODS: This study looks at
the creation ofHTAagencies (e.g. AHRQ,HIQA, IQWiG, PBAC, CADTHandNICE) and
their evolution in terms of roles in assessment (advisory, coordinating, decision-
making) and the relationship they have with appraisal. RESULTS: It has been dem-
onstrated that the time it takes for an agency to generate assessments impacting
patient access varies widely. For example, in Ireland, HIQA was chartered in May
2007, and entrustedwith performingHTA assessments. In 2008 and 2009, HIQA has
published one health technology assessment per year, both ofwhichwere received
and in turn implemented by the Minister for Health and Children. In comparison,
NICE in the UK was founded in 1999, but its appraisals were not supported by
mandate until 2005. Meanwhile, HTAs driven by DAHTA@DIMDI in Germany are
known to rarely play a role in pricing and reimbursement. CONCLUSIONS: The
evolution of HTA bodies has varied from country to country. However, evolution in
scope and impact may provide useful lessons for countries where HTA is receiving
renewed emphasis or where appraisal is under consideration for implementation,
especially as new agencies are created and existing agencies evolve.
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OPTIMIZING THE ORGANIZATION; MIGRATING HEALTH SERVICES RESEARCH
OPERATIONS INTO THE COLLABORATIVE SCIENCE CENTER OF EXCELLENCE
Benson J, Enterline L
Bristol-Myers Squibb, Plainsboro, NJ, USA
The execution and management of Health Services Research projects can be an
onerous task. Often there is no centralized body of knowledge within an organiza-
tion around process and requirements. This leads to long execution timelines,
difficulties with vendors and ultimately reduced productivity. The Collaborative
Science Center of Excellence (CSCoE) was established in 2008 at Bristol-Myers
Squibb (BMS). This group manages the global operations of a wide variety of pro-
grams, a portion of which includes worldwide investigator sponsored research,
non-clinical research, expanded access, and risk evaluation and mitigation pro-
grams. Beginning June 2009, operational management of the entire US Health Eco-
nomics and Outcomes Research (HEOR) book of work was moved from the OR
Scientists into the CSCoE. This included administration, contract execution, mas-
ter service agreement negotiation, financial management, protocol writing, AMCP
dossier updates, and invoice tracking and payment. Within the first year over 90
projectsweremigrated into the CSCoE. Benefits theHealth Services Research group
realized included: 1. A consolidated 2010 and planned 2011 book of work; 2. A
reportable repository of project information; 3. HEOR protocol and AMCP dossier
improvement through standardization of in-house scientific writing; 4. Expedited
contract execution; 5. Innovative cost-sharing; 6. Tiered and batched review of
contracts reduced corporate legal hours; 7. Rapid response to organizational que-
ries. Centralized process management unlocked latent value by allowing OR Sci-
entists to focus on value-added activities, increased organizational transparency
and agility, and moved operations to a lower cost environment.
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DOES ROUTE OF ADMINISTRATION FOR ESTROGEN HORMONE THERAPY
IMPACT RISK OF VENOUS THROMBOEMBOLISM: ESTRADIOL TRANSDERMAL
SYSTEM VERSUS ORAL ESTROGEN-ONLY HORMONE THERAPY
Laliberté F1, Dea K1, Duh MS2, Kahler KH3, Rolli M3, Lefebvre P1
1Groupe d’analyse, Ltée, Montreal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA,
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVES: To evaluate the risk of developing venous thromboembolism (VTE)
events associated with the use of estradiol transdermal system (ETS; Vivelle-Dot®)
relative to oral estrogen-only hormone therapy (HT) agents. METHODS: A health
insurance claims analysis was conducted using the Thomson Reuters MarketScan
database from January 2002 through October 2009. Patients 35 years old newly
initiated on an ETS or oral estrogen-only HT with 2 dispensings were analyzed.
VTE was defined as 1 diagnosis code for deep vein thrombosis or pulmonary
embolism. As a secondary outcome we assessed incident VTE resulting in hospi-
talization. Cohorts of ETS and oral estrogen-only HT were matched 1:1 based on
both exact factor and propensity score matching. Incidence rate ratio (IRR) was
used to compare the rates of VTE between the matched cohorts. Remaining base-
line imbalances from matching were included as covariates in multivariate
adjustments. RESULTS: Among the matched ETS and oral estrogen-only HT users
(27,018 subjects in each group), the mean (SD) ages of the cohorts were 48.9 (7.1)
years; in each cohort 6,044 (22.4%) and 1,788 (6.6%) patients had ahysterectomyand
an oophorectomy at baseline, respectively. The mean (median) drug exposure for
the ETS and oral estrogen-only HT cohorts was 391 (264) and 401 (272) days, respec-
tively. A total of 115 ETS users developed VTE compared to 164 subjects in the
estrogen-only HT cohort (unadjusted IRR: 0.72; 95% CI: 0.57-0.91, P0.006). After
adjustments, ETS remained statistically significantly associated with a lower inci-
dence (33% reduction; P0.0134) of VTE. The incidence rate reduction for hospital-
ization-related VTE events among the ETS users was even more pronounced with
the adjusted incidence being 62% lower for ETS users relative to oral estrogen-only
HTusers.CONCLUSIONS:Results of this large population-based study showed that
patients receiving ETS had a significantly lower incidence of VTE compared to
patients receiving oral estrogen-only HT.
PCV2
THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY
CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS
Chang JY1, Nichol MB2
1University of Southern California, Alhambra, CA, USA, 2University of Southern California, Los
Angeles, CA, USA
OBJECTIVES: Calcium and vitamin D supplements have been widely used and
recommended forwomen to prevent or delay the onset of osteoporosis and the risk
of bone fractures. Other benefits include the improvement of blood pressure and
lipid levels and a lowering of body weight. In theory, the beneficial effects of cal-
cium and vitamin D suggest improvements in cardiovascular health. Recent pub-
lications suggest the contrary and allude to increase serum calcium as a risk factor
for adverse cardiovascular events. This study examines whether the exposure to
these supplements are associated with cardiovascular events. METHODS: The
study was based on California Medicaid (Medi-Cal) fee-for-service administrative
claims data from January 1995 to December 2002. The study population consist of
patients50 years with recorded diagnoses of osteoporosis followed from diagno-
ses date to the end of eligibility. Patients were excluded for prior use of the supple-
ments or diagnosis of cardiovascular events or drug induced osteoporosis. Propen-
sity score matching based on age, gender, elixhauser comorbidities and eligibility
data created case (n 1594) and control groups (n4782). Chi-square analysis was
conducted for comparison of the cardiovascular events defined as ICD9 codes for
myocardial infarction and searchable terms of “cerebral infarction, hemorrhage,
ischemia” for stroke. RESULTS: No statistically significant relationship was found
between the study groups for stroke (p0.56) and myocardial infarction (p0.54).
Components of stroke included cerebral artery occlusion (p0.94), precerebral ar-
tery occlusion (p0.27), intracerebral hemorrhage (p0.23), and subarachnoid
hemorrhage (p0.05). The clinical benefits of the supplements were evident with
subarachnoid hemorrhage with 0 recorded diagnoses in the case group compared
to 12 recorded diagnosis in the control group; however statistical significance was
not established. CONCLUSIONS: The use of calcium and vitamin D supplementa-
tion yielded no relationship to the risk of adverse cardiovascular events. Moreover,
no broad cardio-protective effects can be concluded from the study.
PCV3
RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL
VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF
MEDICARE BENEFICIARIES: A CLAIMS DATA ANALYSIS
Dharmarajan SH, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF
University of Mississippi, University, MS, USA
OBJECTIVES:To examine the difference between typical and atypical antipsychotic
drug use in the risk of hospitalization for venous thromboembolism (VTE) in an
elderly Medicare population.METHODS: This is a retrospective cohort study using
5%national sample of 2006-2007Medicare claims data. Medicare beneficiarieswith
continuous Part A, B, and D enrollment in 2006-2007 and who initiated atypical or
typical antipsychotic drug therapy in July 2006-June 2007 were included. All study
subjects were followed for a period of 180 days from the date of index prescription.
Atypical and typical users were matched on propensity score, calculated using
pre-index demographics, clinical comorbidities, andmedication use. A conditional
logistic regressionmodel stratified on the propensity score-matched pair using the
Greedymatching algorithmwas used to compare the risk of hospitalization for VTE
in new users of atypical and typical antipsychotic drugs. Sensitivity analysis in the
unmatched cohort was performed using propensity score as a continuous, linear
term in logistic regression. RESULTS: A total of 15,637 new users of atypical and
2,337 new users of typical antipsychotic drugs were identified. There were 472
(2.6%) individuals with a hospitalization for VTE during follow-up. 417 were atyp-
ical and 55 were typical antipsychotic users. A 1:1 propensity score match yielded
2,333 matched pairs (4,666 individuals). In the matched cohort, 55 typical and 64
atypical drug users were hospitalized for VTE in the follow up period. Compared to
typical antipsychotic users, users of atypical antipsychoticswere less likely to have
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VTE-related hospitalizations but the results were not statistically significant (odds
ratio: 0.857; 95% CI: 0.596-1.233). Sensitivity analysis results agreed with the pri-
mary findings (odds ratio: 0.831; 95% CI: 0.622-1.110). CONCLUSIONS: The risk of
hospitalization for VTE was found to be similar for users of typical and atypical
antipsychotic medication in this elderly Medicare population.
PCV4
TREATMENT PATTERNS, CLINICAL AND ECONOMIC BURDEN OF VENOUS
THROMBOEMBOLISM IN ABDOMINAL SURGERY PATIENTS
Wang L, Dysinger AH, Du J, Xie L, Baser O
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To examine prophylaxis use as it relates to the clinical and economic
burden of venous thromboembolism (VTE) in abdominal surgery patients.
METHODS: A retrospective study (January 1, 2005 to December 31, 2007) was con-
ducted using a subset of the MarketScan Hospital Drug Database and its linked
outpatient files from the Market Scan Commercial and Medicare Supplemental
database. Patients’ demographics, clinical and discharge statuses were compared
using Chi-square testing and standardized difference. Risk-adjusted healthcare
visits and costs were estimated using the General Linear Model. Potential risk
factors for VTE events were selected using the Cox Proportional Hazard Regression
Model. RESULTS: In patients who underwent abdominal surgery (n49,355),
24,473(49.59%) received anticoagulant therapy during their hospitalization and un-
til 30 days after discharge. VTE events for patients who received anticoagulant
prophylaxis were 4.63% versus 7.02% for patients who did not receive anticoagu-
lant prophylaxis. Compared with patients without VTE in the 6-month follow-up
period, patients with VTE were more likely to be older, have comorbid conditions
including previous VTE, major andminor bleeding, and cancer, and to have higher
baseline health care visits and costs. After risk adjustment for pre-specified cova-
riates, inpatient costs ($16,677 vs. $10,774), outpatient costs ($15,426 vs. $7,424),
pharmacy costs ($2,541 vs. $1,862), and readmission rates (0.23% vs. 0.12%) were
higher in patients who had VTE. In the multivariate analysis, appropriate antico-
agulant prophylaxis use was significantly associated with the reduced risk of VTE
(HR: 0.515).CONCLUSIONS:TheVTE event ratewas lower for patientswho received
prophylaxis compared with those who did not. Since the health care costs of pa-
tients with an event were significantly higher than those of patients without an
event, prophylaxis use is associated with lower health care costs.
PCV5
PREVALENCE, INCIDENCE, AND OUTCOMES OF CRITICAL LIMB ISCHEMIA IN
THE MEDICARE POPULATION IN THE UNITED STATES
Baser O1, Verpillat P2, Wang L1
1STATinMED Research, Ann Arbor, MI, USA, 2Sanofi-Aventis Group, Paris, France
Critical limb ischemia (CLI) is a severe obstruction of the arteries that seriously
decreases blood flow to the extremities resulting in amputation of the affected limb
if left untreated. Despite the severity of the disease, there is a lack of data on
prevalence, incidence and outcomes of CLI in the United States. OBJECTIVES: We
conducted a large population-based study to directly estimate prevalence, inci-
dence and outcomes of CLI in theUnited States.METHODS:Data from January 2006
to December 2008 were extracted from the U.S. Medicare dataset. We estimated 1)
age, gender, race and diabetes-specific CLI prevalence and incidence rates using
the direct standardization method, and 2) factors associated with occurrence of
outcomes (leg revascularization, non-traumatic amputation, andmortality) among
the CLI population, using the Cox proportional hazard regressionmodel. RESULTS:
A total of 68,074 patients were identified with eligible CLI ICD-9 codes in 2007 of
whom 44.53% were diabetic. Analyzing 2 years of data, CLI prevalence and annual
incidence rates in this elderly population were 0.23% (0.28% for male and 0.20% for
female patients) and 0.20% (0.23% and 0.17%), respectively. Just as with prevalence,
incidence increased sharply among beneficiaries aged 65-69 (0.13%) to85 (0.31%),
was around 2.3 times higher in black patients compared to white patients, and 8.6
times higher in diabetic patients compared to non-diabetic patients. The overall
incidence rates of leg revascularization and non-traumatic amputation in the year
after CLI diagnosis were 29.7% and 25.2%, respectively. Compared to revasculariza-
tion, patients who are older, male, black, and have diabetes had a higher probabil-
ity of amputation. 30.3% of the patients died within the first year after CLI
diagnosis. CONCLUSIONS: This first U.S. nationwide-based study shows that prev-
alence, incidence and outcomes are different according to patients’ socio-demo-
graphic characteristics and comorbidities, suggesting that CLI patient manage-
ment varies among the U.S. population.
PCV6
ANALYSIS OF MYOCARDIAL INFARCTION RELATED CLINICAL OUTCOMES,
HEALTH CARE UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR
ATRIAL FIBRILLATION
Wang L, Xie L, Baser O
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To estimate clinical outcomes, healthcare utilization and cost burden
of patients who suffered a myocardial infarction during the 180 days after diagno-
sis of non-valvular atrial fibrillation (NVAF) and compare it with patients who did
not suffer a myocardial infarction. METHODS: Based on 2005-2007 U.S. Medicare
advantage insurance claim files, patients aged 65 years and older who have had
two or more primary diagnoses for NVAF occurring within 30 days of one another
were selected. The 180-day follow-up event rates, healthcare facility use and costs
for patients with a myocardial infarction and those without were compared. Risk
adjustment was performed using the propensity score matching method with the
ProbChoice™ algorithm. RESULTS: In patients who were identified with NVAF
(n18,575), 258 (1.39%) suffered a myocardial infarction during the 180 days after
NVAFdiagnosis. Patientswere not significantly different in terms of gender, region,
and baseline comorbid conditions. After risk-adjustment for pre-specified covari-
ates, mortality (10.08% vs. 0.39% p0.0001), outpatient emergency room (ER) visits
(82.56% vs. 48.06% p0.0001), acute coronary syndrome (63 vs. 2/100 person years),
ischemic stroke (31 vs. 4/100 person years), major bleeding (10 vs. 1/100 person
years) and non-major clinical relevant bleeding (24 vs. 6/100 person years) were all
higher for patients who suffered a myocardial infarction compared to those who
did not. Besides inpatient costs ($26,646 vs. $9,393), risk-adjusted outpatient ER
costs ($1,176 vs. $863) were also higher for myocardial infarction patients. The
overall risk-adjusted difference in health care costs is significant ($36,584 vs.
$10,366 p0.0001). CONCLUSIONS: Most of the adverse events analyzed were
higher for patients who suffered a myocardial infarction after NVAF relative to
patients who did not. Total health care utilization and costs were also significantly
increased.
PCV7
ANALYSIS OF TREATMENT PATTERNS AND COSTS FOR VENOUS
THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENTS IN HOSPITALIZED
MEDICALLY ILL PATIENTS
Baser O, Xie L, Du J, Wang L
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To examine the prophylaxis use, incidence of VTE, major bleeding,
minor bleeding and associated economic burden over 90 days in hospitalizedmed-
ically-ill patients. METHODS: A retrospective study (January 1, 2005 to December
31, 2007) was conducted using a subset of the MarketScan Hospital Drug Database
and its linked outpatient files from the Market Scan Commercial and Medicare
Supplemental database. Eligible patients were selected if they were continuously
enrolled in their health plan for at least 180 days prior to and 90 days following the
index hospital discharge date, which is hospitalization with amedically ill diagno-
sis. Prophylaxis use is defined as the admission date of index hospitalization to 30
days after index hospital discharge and before the date of their first VTE events.
Patients’ demographics, healthcare visits and costs were compared using Chi-
square testing and standardized differences. Risk-adjusted total healthcare costs
betweenpatientswith events andwithoutwere estimated using theGeneral Linear
Model. RESULTS: In patients who were identified as medically ill (n12,077),
6,464(53.52%) received anticoagulant therapy during their hospitalization and until
30 days after discharge. Compared with patients who did not receive any antico-
agulant prophylaxis, patients who received anticoagulant prophylaxis had signif-
icantly lower VTE events (1.47% vs. 3.58%, p0.0001). Although there was no sig-
nificant difference in rates of major bleeding and minor bleeding, after risk-
adjustment for pre-specified covariates, patients with outcome events were
significantly associatedwith higher total health care costs (VTE: $40,523 vs. $17,698
p0.0001; Major bleeding: $27,430 vs. $18,137 p0.0001; Minor bleeding: $25,696 vs.
$17,410 p0.0001). CONCLUSIONS: Despite existing guidelines, few medically-ill
patients are receiving anticoagulant prophylaxis. Appropriate anticoagulant pro-
phylaxis use results in lower VTE event rates and total follow-up health care costs
in hospitalized medically-ill patients.
PCV8
EVALUATION OF A SAFETY INITIATIVE AND OUTCOMES FOR PATIENTS ON
STATIN-FIBRATE COMBINATION THERAPIES IN THE VETERANS AFFAIRS
POPULATION
Yi T, Tran JN, Bounthavong M
Veterans Affairs San Diego Healthcare System, San Diego, CA, USA
OBJECTIVES: Due to the reported higher incidences of adverse events in patients
on combination statins and fibrates compared to statins alone, the Veterans Affairs
(VA) San Diego initiated an intervention to reduce the number of patients on com-
bination therapies. This study aimed to evaluate the effectiveness and safety of
statin-fibrate combination therapies within the VA population. METHODS: This
was a retrospective cohort study of VA medical, pharmacy, and laboratory data.
Patients on a statin and fibrate combination in June 2008 were selected and strat-
ified based on continuation or discontinuation of combination therapy by June
2009. Hyperlipidemic measures, safety measures, and adverse events were ob-
tained pre- and post-intervention. Chi-square and ANOVA tests were utilized to
test between-group differences and paired t-tests were conducted to analyze with-
in-group differences at pre- and post-intervention. Repeatedmeasures regressions
were used to assess longitudinal differences between groups over time. RESULTS:
No differences in rates of cardiovascular diseasewere found between patients who
continued and discontinued combination therapy at baseline and one year later.
No incidences of rhabdomyolysis and pancreatitis were reported. Compared to
those who continued combination therapy, those who discontinued combination
therapy had significantly lower total cholesterol (184 versus 172 mg/dL, p0.029),
higher CK (171 versus 132 U/L, p0.006), and lower triglyceride levels post-inter-
vention. There were no significant longitudinal differences between groups over
time. Within the patients who discontinued combination therapy, AST and ALT
were significantly lower after the intervention while total cholesterol and LDL lev-
els were higher post-intervention. Within those who continued, ALT was lower
while total cholesterol, LDL, andCKwere higher post-intervention.CONCLUSIONS:
Discontinuation of statin-fibrate combination therapy did not have a significant
impact on the management of hyperlipidemia measures and no differences in
adverse events were observed. Further studies should be done to assess the long-
term effects of statin-fibrate combination therapy.
A33V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
